Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trialResearch in context

Summary: Background: Early recognition of risk of death in pneumonia and start of precision immunotherapy to improve outcomes is an unmet need. We hypothesized that a precision strategy approach combining early recognition of interleukin (IL)-1 activation coupled with Anakinra treatment may improve...

Descripció completa

Dades bibliogràfiques

Autors principals:	Georgios Tavoulareas, Olga Kontakou-Zoniou, Nikolaos Antonakos, Elisavet Tasouli, George Adamis, Nikolaos Kakavoulis, Evangelos Michelakis, Ilias Skopelitis, Konstantina Dakou, Christos Psarrakis, Panagiotis Koufargyris, Myrto Astriti, Styliani Sympardi, Evangelos J. Giamarellos-Bourboulis
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-03-01
Col·lecció:	The Lancet Regional Health. Europe
Matèries:	Pneumonia Presepsin Anakinra Organ dysfunction Mortality
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666776225003655
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!